Filtered By:
Condition: Hypertension
Cancer: Prostate Cancer

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 51 results found since Jan 2013.

Nine Easy Ways to Gain Control of Your Health in Your Forties
What lifestyle changes should you make to stay healthy through your 40s? originally appeared on Quora - the knowledge sharing network where compelling questions are answered by people with unique insights. Answer by Keck Medicine of USC, 500+ internationally renowned doctors at a leading academic medical center, on Quora: Getting older has its perks. Chances are you're more confident, have more direction and a defined sense of self. While your health is likely not a primary concern, it's important to take steps now to stop subtle changes before they become major health issues. Your 40s is the decade that your habits sta...
Source: Healthy Living - The Huffington Post - January 9, 2017 Category: Consumer Health News Source Type: news

Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns
ConclusionMGUS is often incidentally detected as part of a work up for other medical conditions, and our results reveal that there is a variety of reasons for which monoclonal testing is performed. With recent developments in our understanding of the significance of monoclonal gammopathy and its association with certain renal and organ damage (Fermand et al., 2018; Leung et al., 2012), there may be a change in how the paraproteinemia investigations are utilized by clinicians in different disciplines. It will be important to recognize and establish appropriate indications for testing. Furthermore, MGUS patients present with...
Source: Blood - November 21, 2018 Category: Hematology Authors: Lee, H., Street, L., Tay, J., Grossman, J., Thaell, J. F., Goodyear, D., McCulloch, S., Duggan, P., Neri, P., Jimenez-Zepeda, V. Tags: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III Source Type: research

Sex Difference of Radiation Response in Occupational and Accidental Exposure
Conclusion and Outlook This review summarizes the data from major human studies on the health risks of radiation exposure and shows that sex can potentially influence the prolonged response to radiation exposure (Figure 1 and Tables 1, 2). These data suggest that long-term radiosensitivity in females is higher than that in males who receive a comparable dose of radiation. Our analysis of the literature agrees with the conclusions of the recent report on the Biological effects of ionizing radiation (BEIR VII) published in 2006 by the National Academy of Sciences (NAS), United States (National Research Council, 2006). The B...
Source: Frontiers in Genetics - May 2, 2019 Category: Genetics & Stem Cells Source Type: research

Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population ‐based propensity score matching study
ConclusionThis nationwide population ‐based study revealed that ADT was not associated with cerebral infarction after adjusting for potential confounders.
Source: Cancer Medicine - June 9, 2019 Category: Cancer & Oncology Authors: Bum Sik Tae, Byeong Jo Jeon, Hoon Choi, Jae Hyun Bae, Jae Young Park Tags: ORIGINAL RESEARCH Source Type: research

Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients.
Conclusion: Better chronic disease management is needed among prostate cancer survivors through more effective survivorship care planning and interventions that promote health behaviors. PMID: 32269460 [PubMed - in process]
Source: Ethnicity and Disease - April 11, 2020 Category: International Medicine & Public Health Tags: Ethn Dis Source Type: research

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Cardiovascular Complications of Prostate Cancer Therapy
AbstractPurpose of reviewWith treatment advances, the most common cause of death in prostate cancer patients is cardiovascular disease. Discerning the contribution of prostate cancer treatment on cardiovascular complications versus the natural progression of cardiovascular disease remains an ongoing area of investigation. Evaluating the research and identifying opportunities for further investigation is critical for optimal care of this prostate cancer patient population.Recent findingsThe degree that hormone therapy contributes to cardiovascular morbidity and mortality remains uncertain with conflicting results from large...
Source: Current Treatment Options in Cardiovascular Medicine - November 12, 2020 Category: Cardiology Source Type: research

Cardiovascular Toxicity of Androgen Deprivation Therapy
AbstractPurpose of ReviewAndrogen deprivation therapy (ADT) is the standard of care for the treatment of advanced prostate cancer (PC). ADT, particularly with GnRH agonists, leads to increased risk of cardiovascular disease, including myocardial infarction, hypertension, and stroke. This review discusses the options of ADT, the mechanism of ADT-associated cardiovascular side effects, and potential benefit by using GnRH antagonists.Recent FindingsGnRH antagonists have relatively less cardiovascular adverse effects compared to GnRH agonists. We highlight on a recently published phase III clinical trial on the oral GnRH antag...
Source: Current Cardiology Reports - July 3, 2021 Category: Cardiology Source Type: research

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

The relationship between the severity of insomnia and falls in the elderly - İleri, Borazan FY, Cavusoglu C, Göker B.
BACKGROUND: Insomnia is associated with depression, cognitive impairment, hypertension, myocardial infarction, stroke, metabolic syndrome and prostate cancer in the elderly. The aim of this study is to investigate the relationship between severity of insom...
Source: SafetyLit - October 11, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

' Chipping away ' at the iceberg of health disparities
'Chipping away' at the iceberg of health disparities Kelly Palmer joined the Mel and Enid Zuckerman College of Public Health faculty in January, not long after earning her doctorate from the college. As a researcher studying diseases that disproportionately affect Black women, Palmer says her work is a team effort – and incredibly personal. Kyle Mittan Today University CommunicationsPalmer-web.jpg"Black women are my mother, my sister, my cousin, the members of my sorority, Alpha Kappa Alpha," said Kelly Palmer, an assistant professor in the University of Arizona Mel and Enid Zuckerman College of P...
Source: The University of Arizona: Health - February 14, 2022 Category: Universities & Medical Training Authors: mittank Source Type: research